TMDX - TransMedics Group Inc Stock Price, Fair Value and News

88.88USD-1.72 (-1.90%)Market Closed

Market Summary

USD88.88-1.72

Market Closed

-1.90%

TMDX Alerts

3 major insider sales recently.

TMDX Stock Price

View Fullscreen

TMDX RSI Chart

TMDX Valuation

Market Cap

2.9B

Price/Earnings (Trailing)

-116.18

Price/Sales (Trailing)

12.03

EV/EBITDA

-384.27

Price/Free Cashflow

-17.64

TMDX Price/Sales (Trailing)

TMDX Profitability

Operating Margin

63.77%

EBT Margin

-11.04%

Return on Equity

-18.24%

Return on Assets

-3.54%

Free Cashflow Yield

-5.67%

TMDX Fundamentals

TMDX Revenue

Revenue (TTM)

241.6M

Rev. Growth (Yr)

158.72%

Rev. Growth (Qtr)

22.19%

TMDX Earnings

Earnings (TTM)

-25.0M

Earnings Growth (Yr)

159.99%

Earnings Growth (Qtr)

115.86%

Breaking Down TMDX Revenue

Last 7 days

1.2%

Last 30 days

25.1%

Last 90 days

3.9%

Trailing 12 Months

6.9%

How does TMDX drawdown profile look like?

TMDX Financial Health

Current Ratio

9.3

Debt/Equity

3.26

Debt/Cashflow

-0.03

TMDX Investor Care

Shares Dilution (1Y)

1.61%

Diluted EPS (TTM)

-0.77

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	119.1M	151.1M	191.8M	241.6M
2022	39.1M	51.4M	71.8M	93.5M
2021	25.2M	29.9M	28.2M	30.3M
2020	26.5M	24.2M	24.1M	25.6M
2019	15.2M	17.9M	21.1M	23.6M
2018	0	0	0	13.0M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of TransMedics Group Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 17, 2024	hassanein waleed h	acquired	53,120	13.28	4,000	president & ceo
Apr 17, 2024	hassanein waleed h	sold	-380,480	95.12	-4,000	president & ceo
Apr 10, 2024	hassanein waleed h	acquired	159,360	13.28	12,000	president & ceo
Apr 10, 2024	hassanein waleed h	sold	-1,141,080	95.09	-12,000	president & ceo
Apr 09, 2024	khayal tamer i	acquired	410,420	26.4583	15,512	chief commercial officer
Apr 09, 2024	khayal tamer i	sold	-1,403,080	90.4514	-15,512	chief commercial officer
Apr 08, 2024	khayal tamer i	acquired	70,822	16.14	4,388	chief commercial officer
Apr 08, 2024	khayal tamer i	sold	-394,920	90.00	-4,388	chief commercial officer
Apr 04, 2024	khayal tamer i	sold	-397,541	80.36	-4,947	chief commercial officer
Apr 04, 2024	khayal tamer i	acquired	74,038	14.9664	4,947	chief commercial officer

Which funds bought or sold TMDX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	AMALGAMATED BANK	reduced	-77.17	-284,000	77,000	-%
Apr 23, 2024	Values First Advisors, Inc.	added	12.65	37,765	721,695	0.42%
Apr 23, 2024	Global Retirement Partners, LLC	added	21.52	834	7,098	-%
Apr 23, 2024	Venturi Wealth Management, LLC	new	-	29,576	29,576	-%
Apr 23, 2024	ARCADIA INVESTMENT MANAGEMENT CORP/MI	reduced	-0.36	-5,795	81,852	0.01%
Apr 22, 2024	Raymond James Financial Services Advisors, Inc.	added	59.85	677,343	2,039,040	-%
Apr 22, 2024	Oakworth Capital, Inc.	unchanged	-	-2,056	30,463	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	400,131	1,306,130	0.01%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	added	102	324,230	686,755	-%
Apr 19, 2024	Financial Perspectives, Inc	sold off	-100	-371,716	-	-%

Are Funds Buying or Selling TMDX?

Are funds buying TMDX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TMDX

No. of Funds

TMDX Alerts

3 major insider sales recently.

Unveiling TransMedics Group Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	macquarie group ltd	4.67%	1,525,793	SC 13G/A
Feb 13, 2024	vanguard group inc	5.71%	1,865,115	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 25, 2024	blackrock inc.	7.8%	2,550,255	SC 13G/A
Feb 14, 2023	macquarie group ltd	6.10%	1,947,418	SC 13G/A
Feb 10, 2023	sandhill capital partners llc	3.8%	1,203,750	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	5.30%	1,691,425	SC 13G
Feb 03, 2023	blackrock inc.	7.2%	2,310,705	SC 13G/A
Feb 02, 2023	credit suisse ag/	3.24%	1,037,297	SC 13G/A

Recent SEC filings of TransMedics Group Inc

View All Filings

Date Filed	Form Type	Document
Apr 18, 2024	4	Insider Trading
Apr 12, 2024	4	Insider Trading
Apr 10, 2024	144	Notice of Insider Sale Intent
Apr 10, 2024	4	Insider Trading
Apr 10, 2024	ARS	ARS
Apr 10, 2024	DEF 14A	DEF 14A
Apr 10, 2024	DEFA14A	DEFA14A
Apr 08, 2024	144	Notice of Insider Sale Intent
Apr 05, 2024	4	Insider Trading
Apr 03, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to TransMedics Group Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	185.5B	40.1B	-2.82%	-2.78%	32.41	4.63	-8.12%	-17.45%
BDX	67.5B	19.5B	-3.26%	-10.41%	53.77	3.46	4.02%	-22.04%
ALGN	23.6B	3.9B	-1.72%	-10.74%	52.95	6.1	3.42%	23.09%
BAX	20.8B	14.8B	-2.03%	-9.90%	7.83	1.4	2.12%	209.17%
MID-CAP
HSIC	9.4B	12.3B	0.44%	-12.46%	22.62	0.76	-2.44%	-22.68%
ATR	9.2B	3.5B	-2.07%	18.57%	32.49	2.65	4.97%	18.89%
BIO	8.1B	2.7B	-18.49%	-36.41%	-12.74	3.04	-4.68%	82.43%
XRAY	6.4B	4.0B	-5.85%	-24.53%	-47.67	1.62	1.10%	85.84%
AXNX	3.4B	366.4M	-3.04%	14.62%	-560.04	9.28	33.86%	89.83%
PDCO	2.3B	6.6B	-3.54%	-1.62%	12.12	0.36	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-13.37%	-14.88%	-1.92	0.41	7.73%	-1066.14%
ANIK	384.6M	166.7M	3.23%	-3.00%	-4.65	2.31	6.67%	-456.34%
ANGO	235.1M	324.0M	11.39%	-31.43%	-1.22	0.73	-3.19%	-337.41%
APYX	52.0M	52.3M	18.11%	-48.10%	-2.78	0.99	17.61%	19.28%
AEMD	4.0M	3.7M	-12.07%	240.00%	-0.33	1.07	5.77%	8.23%

TransMedics Group Inc News

Latest updates

TransMedics Group Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	22.2%	81,174,000	66,430,000	52,465,000	41,554,000	31,375,000	25,683,000	20,521,000	15,880,000	9,668,000	5,370,000	8,171,000	7,053,000	7,627,000	7,091,000	3,391,000	7,530,000	6,057,000	7,205,000	5,666,000	4,676,000	3,544,000
Cost Of Revenue	29.0%	33,250,000	25,768,000	15,724,000	12,788,000	10,672,000	7,568,000	6,171,000	3,776,000	2,682,000	1,597,000	2,582,000	2,242,000	2,799,000	2,053,000	1,482,000	2,670,000	2,316,000	2,989,000	2,333,000	2,103,000	2,045,000
Gross Profit	17.9%	47,924,000	40,662,000	36,741,000	28,766,000	20,703,000	18,115,000	14,350,000	12,104,000	6,986,000	3,773,000	5,589,000	4,811,000	4,828,000	5,038,000	1,909,000	4,860,000	3,741,000	4,216,000	3,333,000	2,573,000	1,499,000
Operating Expenses	-34.3%	45,321,000	68,997,000	37,647,000	30,855,000	27,482,000	23,659,000	24,095,000	21,473,000	18,314,000	15,498,000	15,457,000	11,318,000	10,724,000	9,648,000	9,770,000	12,877,000	12,435,000	11,458,000	11,038,000	8,535,000	7,860,000
S&GA Expenses	12.7%	34,560,000	30,653,000	29,356,000	24,984,000	21,726,000	16,851,000	17,381,000	13,939,000	12,000,000	10,335,000	9,162,000	6,786,000	6,176,000	5,493,000	5,867,000	6,652,000	6,173,000	6,519,000	6,251,000	4,653,000	4,374,000
R&D Expenses	-3.3%	10,761,000	11,132,000	8,291,000	5,871,000	5,756,000	6,808,000	6,714,000	7,534,000	6,314,000	5,163,000	6,295,000	4,532,000	4,548,000	4,155,000	3,903,000	6,225,000	6,262,000	4,939,000	4,787,000	3,882,000	3,486,000
EBITDA Margin	73.6%	-0.03	-0.12	-0.05	-0.17	-0.31	-0.50	-0.81	-1.05	-1.27	-1.14	-0.81	-0.88	-	-	-	-	-	-	-	-	-
Interest Expenses	0.4%	3,605,000	3,590,000	2,505,000	1,091,000	1,007,000	787,000	972,000	960,000	978,000	979,000	965,000	952,000	971,000	971,000	1,001,000	1,042,000	1,063,000	1,084,000	1,113,000	1,093,000	1,073,000
Income Taxes	88.9%	-168,000	-1,507,000	21,000	11,000	19,000	19,000	22,000	6,000	17,000	9,000	6,000	4,000	10,000	6,000	6,000	10,000	10,000	10,000	10,000	10,000	18,000
Earnings Before Taxes	114.3%	3,863,000	-26,929,000	-980,000	-2,625,000	-6,701,000	-7,407,000	-11,501,000	-10,556,000	-12,651,000	-12,953,000	-10,662,000	-7,913,000	-6,301,000	-5,082,000	-8,491,000	-8,842,000	-9,167,000	-8,270,000	-9,185,000	-6,885,000	-7,617,000
EBT Margin	43.1%	-0.11	-0.19	-0.12	-0.24	-0.39	-0.59	-0.93	-1.20	-1.46	-1.34	-1.00	-1.10	-	-	-	-	-	-	-	-	-
Net Income	115.9%	4,031,000	-25,422,000	-1,001,000	-2,636,000	-6,720,000	-7,426,000	-11,523,000	-10,562,000	-12,668,000	-12,962,000	-10,668,000	-7,917,000	-6,311,000	-5,088,000	-8,497,000	-8,852,000	-9,177,000	-8,280,000	-9,195,000	-6,895,000	-7,635,000
Net Income Margin	44.5%	-0.10	-0.19	-0.12	-0.24	-0.39	-0.59	-0.93	-1.20	-1.46	-1.34	-1.00	-1.11	-	-	-	-	-	-	-	-	-
Free Cashflow	70.8%	-33,514,000	-114,590,000	-7,183,000	-9,588,000	-6,799,000	-17,212,000	-13,354,000	-20,359,000	-9,826,000	-9,418,000	-5,789,000	-7,350,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	2.4%	706	689	690	287	277	275	117	124	135	131	141	146	152	159	163	97.00	105	113	121	39.00	42.00
Current Assets	-4.9%	511	537	663	262	252	251	95.00	106	119	126	135	141	147	154	158	92.00	100	107	116	30.00	35.00
Cash Equivalents	-7.6%	395	427	582	195	201	204	30.00	18.00	26.00	22.00	25.00	27.00	25.00	21.00	51.00	25.00	21.00	20.00	47.00	12.00	21.00
Inventory	12.4%	44.00	39.00	31.00	24.00	21.00	19.00	17.00	17.00	15.00	15.00	13.00	12.00	12.00	13.00	13.00	11.00	11.00	11.00	11.00	11.00	9.00
Net PPE	32.8%	174	131	20.00	19.00	19.00	18.00	16.00	12.00	10.00	5.00	5.00	5.00	5.00	5.00	4.00	5.00	5.00	5.00	4.00	4.00	3.00
Goodwill	2.7%	12.00	12.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Liabilities	1.1%	569	563	545	94.00	90.00	87.00	66.00	64.00	67.00	53.00	52.00	48.00	48.00	50.00	49.00	50.00	51.00	49.00	50.00	51.00	48.00
Current Liabilities	11.9%	55.00	49.00	32.00	29.00	24.00	21.00	23.00	20.00	23.00	16.00	15.00	12.00	12.00	14.00	14.00	15.00	16.00	15.00	15.00	16.00	13.00
Long Term Debt	0.2%	447	446	446	59.00	59.00	59.00	35.00	35.00	35.00	35.00	35.00	35.00	35.00	35.00	34.00	34.00	34.00	34.00	34.00	34.00	34.00
LT Debt, Non Current	0.2%	447	446	446	59.00	59.00	59.00	35.00	35.00	35.00	35.00	35.00	35.00	35.00	35.00	34.00	34.00	34.00	34.00	34.00	34.00	34.00
Shareholder's Equity	8.5%	137	126	145	193	187	188	51.00	60.00	68.00	79.00	89.00	98.00	104	110	114	47.00	55.00	63.00	71.00	-	-
Retained Earnings	0.8%	-503	-507	-482	-481	-478	-472	-464	-453	-442	-429	-416	-406	-398	-391	-386	-378	-369	-360	-352	-342	-335
Shares Outstanding	0.1%	33.00	33.00	33.00	33.00	32.00	29.00	28.00	28.00	28.00	28.00	27.00	27.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	2,641	-	-	-	841	-	-	-	858	-	-	-	454	-	-	-	454	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	220.9%	8,304	-6,868	-5,803	-8,661	-4,035	-14,282	-9,094	-18,406	-6,648	-9,350	-5,536	-7,330	-7,138	-6,412	-8,539	-8,176	-7,264	-5,597	-12,159	-7,266	-6,120
Share Based Compensation	10.3%	5,724	5,188	4,958	3,921	2,991	2,704	2,316	2,310	1,985	1,973	1,808	1,112	698	700	631	385	282	295	220	57.00	52.00
Cashflow From Investing	72.1%	-41,818	-149,828	-1,380	-927	-2,764	24,748	22,015	10,514	9,992	6,199	3,804	9,272	9,884	-23,473	-40,724	12,715	7,360	-18,765	-49,093	-3.00	-134
Cashflow From Financing	-39.3%	924	1,523	394,013	3,958	3,065	164,220	237	405	45.00	552	213	583	33.00	-179	75,543	152	-246	-2,428	96,094	-697	-2,280

TMDX Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue:
Total revenue	$ 241,623	$ 93,459	$ 30,262
Cost of revenue:
Total cost of revenue	87,530	28,187	9,103
Gross profit	154,093	65,272	21,159
Operating expenses:
Research, development and clinical trials	36,055	26,812	22,304
Acquired in-process research and development expenses	27,212
Selling, general and administrative	119,553	69,897	38,283
Total operating expenses	182,820	96,709	60,587
Loss from operations	(28,727)	(31,437)	(39,428)
Other income (expense):
Interest expense	(10,791)	(3,726)	(3,874)
Other income (expense), net	12,847	(1,002)	(877)
Total other income (expense), net	2,056	(4,728)	(4,751)
Loss before income taxes	(26,671)	(36,165)	(44,179)
(Provision) benefit for income taxes	1,643	(66)	(36)
Net loss	$ (25,028)	$ (36,231)	$ (44,215)
Net loss per share attributable to common stockholders, basic	$ (0.77)	$ (1.23)	$ (1.6)
Net loss per share attributable to common stockholders, diluted	$ (0.77)	$ (1.23)	$ (1.6)
Weighted average common shares outstanding, basic	32,517,372	29,556,633	27,616,839
Weighted average common shares outstanding, diluted	32,517,372	29,556,633	27,616,839
Net product revenue [Member]
Revenue:
Total revenue	$ 176,069	$ 79,234	$ 29,657
Cost of revenue:
Total cost of revenue	41,015	16,970	9,031
Service Revenue [Member]
Revenue:
Total revenue	65,554	14,225	605
Cost of revenue:
Total cost of revenue	$ 46,515	$ 11,217	$ 72

TMDX Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash	$ 394,812	$ 201,182
Accounts receivable	63,576	27,611
Inventory	44,235	20,605
Prepaid expenses and other current assets	8,031	2,896
Total current assets	510,654	252,294
Property, plant and equipment, net	173,941	19,223
Operating lease right-of-use assets	6,546	5,130
Restricted cash	500	500
Goodwill	11,990
Acquired intangible assets, net	2,354
Other non-current assets	62
Total assets	706,047	277,147
Current liabilities:
Accounts payable	12,717	3,341
Accrued expenses and other current liabilities	38,221	18,635
Deferred revenue	1,961	241
Operating lease liabilities	2,035	1,444
Total current liabilities	54,934	23,661
Convertible senior notes, net	447,140
Long-term debt, net	59,064	58,696
Operating lease liabilities, net of current portion	7,707	7,415
Total liabilities	568,845	89,772
Commitments and contingencies (Note 13)
Stockholders’ equity:
Preferred stock, no par value; 25,000,000 shares authorized; no shares issued or outstanding
Common stock, no par value; 150,000,000 shares authorized; 32,670,803 shares and 32,141,368 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	641,106	666,277
Accumulated other comprehensive loss	(199)	(225)
Accumulated deficit	(503,705)	(478,677)
Total stockholders’ equity	137,202	187,375
Total liabilities and stockholders’ equity	$ 706,047	$ 277,147

About TransMedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

CEO	Dr. Waleed H. Hassanein M.D.
WEBSITE	transmedics.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	212

TransMedics Group Inc Frequently Asked Questions

What is the ticker symbol for TransMedics Group Inc? What does TMDX stand for in stocks?

TMDX is the stock ticker symbol of TransMedics Group Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of TransMedics Group Inc (TMDX)?

As of Wed Apr 24 2024, market cap of TransMedics Group Inc is 2.91 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TMDX stock?

You can check TMDX's fair value in chart for subscribers.

What is the fair value of TMDX stock?

You can check TMDX's fair value in chart for subscribers. The fair value of TransMedics Group Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of TransMedics Group Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TMDX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is TransMedics Group Inc a good stock to buy?

The fair value guage provides a quick view whether TMDX is over valued or under valued. Whether TransMedics Group Inc is cheap or expensive depends on the assumptions which impact TransMedics Group Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TMDX.

What is TransMedics Group Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 24 2024, TMDX's PE ratio (Price to Earnings) is -116.18 and Price to Sales (PS) ratio is 12.03. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TMDX PE ratio will change depending on the future growth rate expectations of investors.